Yonghao Yang Hao Huang Tiepeng Li Quanli Gao Yongping Song Zibing Wang
10.3389/fimmu.2021.728750
Front Immunol
2021 Oct 26;12:728750.
pd-1 anti-angiogenic axitinib immunotherapy low-dose resistance
CC BY
https://pubmed.ncbi.nlm.nih.gov/34764951/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Axitinib / therapeutic use Carcinoma, Renal Cell / drug therapy Drug Resistance, Neoplasm Immune Checkpoint Inhibitors / therapeutic use Kidney Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Protein Kinase Inhibitors / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Axitinib / therapeutic use Carcinoma, Renal Cell / drug therapy Drug Resistance, Neoplasm Immune Checkpoint Inhibitors / therapeutic use Kidney Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Protein Kinase Inhibitors / therapeutic use Case Reports Research Support, Non-U.S. Gov't Review Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Combined Chemotherapy Protocols / adverse effects Carcinoma, Renal Cell / immunology Carcinoma, Renal Cell / metabolism Carcinoma, Renal Cell / secondary Chemotherapy, Adjuvant Female Humans Immune Checkpoint Inhibitors / adverse effects Kidney Neoplasms / immunology Kidney Neoplasms / metabolism Kidney Neoplasms / pathology Middle Aged Programmed Cell Death 1 Receptor / metabolism Treatment Outcome Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor Protein Kinase Inhibitors sintilimab Axitinib
PMC8576543
34764951
Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
2021